Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol
Medical Sciences · 23.07.2026 · 14 (4) · 421
DOI: 10.3390/medsci14040421 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Medical Sciences, online erschienen am 23.07.2026. Verfasst von Tamás Jámbor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Surgical Research, Albert Szent-Györgyi Medical School, University of Szeged, 6720 Szeged, Hungary. Hauptthemen laut MEDLINE: Allopurinol, Sodium-Glucose Transporter 2 Inhibitors, Uric Acid, Hyperuricemia. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Szeged.
Abstract (Originalsprache)
Background
Hyperuricemia has long been linked to the progression of chronic kidney disease (CKD), although the role of serum uric acid (sUA) reduction in kidney preservation remains uncertain. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower sUA levels and exert renoprotective effects, but it is unclear whether these findings are mechanistically related.
Methods
Adult patients with type 2 diabetes mellitus and hyperuricemia were included from a retrospective cohort. Patients treated with empagliflozin (n = 70) or dapagliflozin (n = 78) were pooled into a single group and compared with an allopurinol-treated group (n = 66). Exploratory mediation-informed analysis models assessed associations between treatment, changes in sUA (ΔsUA), and changes in estimated glomerular filtration rate (ΔeGFR) at 12 and 36 months. Dose–response and nonlinear associations between ΔsUA and ΔeGFR were additionally examined.
Results
At 12 months, SGLT2 inhibitor treatment was associated with greater ΔsUA compared with allopurinol (B = 22.62, p = 0.040); its direct association with ΔeGFR remained significant after adjustment for ΔsUA (B = −6.14, p < 0.001). At 36 months, the association of treatment with ΔsUA was no longer significant, whereas association with ΔeGFR persisted (B = −11.8, p < 0.001). No dose–response or nonlinear relationship was identified between ΔsUA and ΔeGFR, while treatment remained an independent predictor of ΔeGFR at both time points.
Conclusions
Reductions in sUA do not appear to mediate the renoprotective effects of SGLT2 inhibitors. The preservation of kidney function associated with SGLT2 inhibitor therapy is likely driven by mechanisms independent of sUA lowering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Surgical Research, Albert Szent-Györgyi Medical School, University of Szeged, 6720 Szeged, Hungary.
- Department of Internal Medicine, Hódmezővásárhely-Makó Healthcare Center, 6900 Makó, Hungary.
- Department of Medical Physics and Informatics, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary.
ORCID-Profile: Tamás Lantos, Andrea Szabó, Roland Fejes
Förderung
- University of Szeged
Zitieren
APA
Jámbor, T., Tallósy, S. P., Lantos, T., Szabó, A., & Fejes, R. (2026). Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol. Medical Sciences, 14(4), 421. https://doi.org/10.3390/medsci14040421
Vancouver
Jámbor T, Tallósy SP, Lantos T, Szabó A, Fejes R. Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol. Medical Sciences. 2026;14(4):421. doi:10.3390/medsci14040421
BibTeX
@article{Jmbor2026,
author = {Jámbor, Tamás and Tallósy, Szabolcs Péter and Lantos, Tamás and Szabó, Andrea and Fejes, Roland},
title = {Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {4},
pages = {421},
doi = {10.3390/medsci14040421}
}
EUVIMED